Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X™ CAREsystem
Fresenius Medical Care (FME), the world’s leading provider of products and services for individuals with renal diseases, today begins the second phase of the company’s efforts to introduce high-volume hemodiafiltration (HVHDF) kidney replacement therapy across the United States. The company last week received FDA 510(k) clearance for the updated version of its new, hemodiafiltration-capable 5008X CAREsystem with additional features, a key benchmark enabling the next steps in the company’s broader commercialization efforts across the U.S. later this year, followed by a full-scale commercial launch in 2026. Fresenius Medical Care first received 510(k) clearance for its 5008X CAREsystem in February 2024, which allowed the company to conduct focused testing, clinical evaluations, and user-studies of the device in a pilot clinic. Last week’s May 2025 FDA 510(k) notice provided clearance for an updated 5008X CAREsystem with additional features, including the Fresenius Clinical…

